Lastet - General Information:A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Lastet inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Lastet acts primarily in the G2 and S phases of the cell cycle. [PubChem]
Other Brand Names containing Etoposide
Lastet - Pharmacology:
Lastet inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis at the premitotic stage of cell division. Lastet is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division.
Lastet for patients
Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.
Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride). High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
ETOPOPHOS (etoposide phosphate) for Injection is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide, etoposide phosphate, or any other component of the formulations.
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..